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Abstract: Follow-up studies after the Chernobyl and Fukushima accidents have shown that 137Cs and
131I made up the major amount of harmful contaminants in the atmospheric dispersion and fallout.
Other potential sources for such radionuclide exposure may be terrorist attacks, e.g., via contamination
of drinking water reservoirs. A primary purpose of radionuclide mobilization is to minimize the
radiation dose. Rapid initiation of treatment of poisoned patients is imperative after a contaminating
event. Internal contamination with radioactive material can expose patients to prolonged radiation,
thus leading to short- and long-term clinical consequences. After the patient’s emergency conditions
are addressed, the treating physicians and assisting experts should assess the amount of radioactive
material that has been internalized. This evaluation should include estimation of the radiation dose
that is delivered and the specific radionuclides inside the body. These complex assessments warrant
the reliance on a multidisciplinary approach that incorporates regional experts in radiation medicine
and emergencies. Regional hospitals should have elaborated strategies for the handling of radiation
emergencies. If radioactive cesium is a significant pollutant, Prussian blue is the approved antidote
for internal detoxification. Upon risks of radioiodine exposure, prophylactic or immediate treatment
with potassium iodide tablets is recommended. Chelators developed from calcium salts have been
studied for gastrointestinal trapping and enhanced mobilization after strontium exposure.
Keywords: cesium; radioactive terrorism; radiation dosage; chelation therapy; iodine; strontium;
Prussian blue
1. Introduction
Although radioactive elements may occur naturally in the environment, most of the harmful
radionuclides are of anthropogenic origin, released from military, industrial or medical processes [1].
Nuclear reactor accidents can lead can lead to workers’ exposure. However, in recent years great
concerns have been raised regarding contamination of the general environment. Reports after the
Chernobyl and Fukushima accidents revealed that the radioisotopes 137Cs and 131I made up the major
amount of harmful contaminants in the air dispersion and fallout [2]. Today, terrorist attacks may
represent another potential source for radionuclide exposure of larger populations, e.g., through
contamination of drinking water. A nuclear explosion by terrorists is a worst-case scenario. Also,
inadvertent exposure due to radiation from radioactive sources used in a medicine or industry may
happen. Human uptake of radionuclides may occur via contaminated food or dust. A primary purpose
of emergency therapy mobilization is to minimize the radiation dose of contaminated individuals [3–5].
Nuclear incidents occur infrequently and some occur very rarely. However, when they do occur, they
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cause a considerable amount of fear and concern in the public and among emergency physicians
and assistant staff, which is partly due to suboptimal healthcare knowledge among the staff about
evaluation and care of the victims [6].
The aim of the present review is to give an update of therapeutic and prophylactic measures for
obtaining radionuclide protection and mobilization of cesium and iodine from exposed individuals
after accidents. Problems related to strontium mobilization are only briefly commented on.
2. General Principles in Therapy of Contaminated Cases
Emergency department staff members who initially evaluate patients contaminated with
radioactive material should work closely with a nuclear medicine expert. This expert should be an
integral part of the team receiving exposed patients in a dedicated area of the emergency department.
The trained staff in CBRN medicine, which includes medical handling of patients after Chemical,
Biological, Radiological and Nuclear accidents, in case of nuclear accidents should work in close
cooperation with the expert in nuclear medicine, who should take part in the important administrative
steps, which can be summarized as follows [5]:
(a) Define a radiation work area or room;
(b) Define personal protective equipment;
(c) Introduce individual dosimeters to staff members;
(d) Monitor contamination on patients.
In an emergency situation, a limit for the radiation dose to the emergency staff is not set when they
perform the initial life-saving activities. However, a cumulative dose limit (0.5 Gy) has been suggested
as a decision point for the team leader when considering how to proceed after an initial time period of
about 60 min [5].
Contaminated clothes of a patient are removed carefully and stored away. Radiation monitoring
may then be necessary to locate any skin or wound contamination. Decontamination of the skin with
water and soap, and of wounds with physiological saline will help to decrease the risk of additional
intake of radioactive material into the body and to decrease the total radiation exposure. Cleaning of
wounds should be done with care. All water used for the external cleaning is collected and treated as
contaminated material. After the external decontamination, the radiation monitoring is repeated to
ensure that external purification can be discontinued.
As soon as a patient is externally decontaminated, a clinician specialized in nuclear and/or CBRN
medicine needs to assess whether the patient is internally contaminated with radioactive material.
The goal of assessing internal contamination is to evaluate whether the patient has taken up hazardous
amounts of the material to deliver a significant dose of radiation to the body or to specific organs,
like the thyroid gland in the case of radioactive iodine. The clinical concern includes also long-term
consequences like cancer. Cancer may result from cumulative radiation dose over time. The clinician
should consider therapies that facilitate the removal of the radioactive material.
The presence as regards type and amount of radioactive material inside the body can be assessed
directly when the patient remains in the radiation area, by using an external radiation detector such as
a hand-held radiation Geiger counter, provided that the element emits gamma rays. Nuclear medicine
departments of regional hospitals potentially have equipment that can be adapted for the diagnosis
of internal contamination and internal dose assessment, for example, thyroid scanners or gamma
cameras otherwise used for SPECT imaging, but these more accurate determinations may require that
the externally decontaminated patient is carefully transported to the specialized department.
The management of internal contamination includes, in addition to supportive care, measures
to decrease the radiation dose that is delivered to body organs and tissues. This measurement can
be achieved by decreasing the absorption of the radioactive element from the gastrointestinal tract
or by enhancing excretion in urine or feces, or by blocking the incorporation into specific organs.
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The approaches recommended for mobilization of radioactive species of cesium and iodine, which
dominate in the environment after nuclear reactor accidents, are discussed below.
3. Radioactive Cesium Contamination
Cesium (Cs, atomic number 55) in Group 1 of the periodic table of elements has standard atomic
weight 132.9. It occurs as the monovalent cation Cs+ in chemical compounds. Chemically, Cs has
similarities with other elements in Group 1, such as sodium and potassium. It is a soft, malleable,
silvery white metal with melting point as low as 28.4 ◦C. Cesium has 40 known isotopes, of which
only 133Cs is stable. After nuclear reactor accidents, the 137Cs isotope is considered a most dangerous
pollutant in the fallouts. The 137Cs isotope has physical half-life of about 30 years, whereas 134Cs has a
shorter half-life of about 2 years. Fission of uranium and plutonium in nuclear reactors and nuclear
weapons due to neutron absorption creates numerous fission products, including 134Cs and 137Cs.
The first one of these two isotopes, 134Cs, decays with both β and γ emission. The second one, 137Cs,
also decays with β and γ emissions, to the metastable 137mBa. After the Chernobyl and Fukushima
accidents, the 137Cs isotope was among the most important environmental pollutants [2] (Figure 1).
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groups containing oxygen and also to some extent nitrogen atoms. Prussian blue, also known as Berlin
blue, with appropriate donor groups is anticipated to be a therapeutically useful antidote according to
the theory, provided that it is administered early after intake, to trap the metal in the gut and thus also
from blood due to the enterohepatic circulation of the element. Nielsen et al. [11] studied effects of
two Prussian blue derivatives on intestinal absorption of 134Cs in two male volunteers. Their results
indicated that administration of Prussian blue (0.5 g) simultaneously with the test meal decreased
134Cs uptake to about 50%, and that daily administration of 0.5 g × 3 decreased the elimination half
time of previously absorbed 134Cs from about 100 to about 50 days. Melo et al. [12] investigated the
effect of age on the decontamination effect of Prussian blue using male beagle dogs injected with 137Cs.
The studied dogs were either immature (about 5 months), young adults (about 2.5 years), or aged
(13.5 years). The researchers observed that 137Cs excretion rates decreased with increasing age. Thus,
the reductions in whole-body levels from Prussian blue chelation were 51% in immature, 31% in young
adults and 38% in aged dogs. Prussian blue changed the ratio of fecal to urinary 137Cs excretion from
0.8 in untreated dogs to 2.2 in treated animals. The hepatic 137Cs levels were reduced in all chelated
dogs. Indirectly, Prussian blue will also mobilize 137Cs from the bloodstream by intervening with its
enterohepatic circulation [13].
Le Gall et al. [14] compared the 137Cs-mobilizing effect of apple-pectin and Prussian blue in rats
intravenously injected with 5 kBq of 137Cs. The mobilizing agents were given in drinking water at
a dose of 400 mg/kg per day during an 11-day period, starting immediately after the Cs injection.
Prussian blue increased the fecal Cs excretion by a factor of five, whereas Cs elimination after the
apple-pectin treatment was not increased compared with untreated rats.
After the Goiania accident in Brazil in 1987, where a radiotherapy source containing an estimated
50.9 TBq of 137Cs was stolen from an abandoned hospital and broken open, Brandao-Mello et al. [15]
and Farina et al. [16] described promising results of early oral treatment with Prussian blue of some of
the exposed patients. After this accident, 249 cases out of 112,000 people examined for contamination
had significant internal or external radioactive contamination [17]. Internal contamination was verified
by the analysis of urine and fecal samples and in a whole-body counter. The first report described
14 patients who developed severe bone marrow depression with neutropenia and thrombocytopenia.
Eight of these received intravenous granulocyte-macrophage colony-stimulating factor; none had bone
marrow transplantation. Four died from hemorrhage and infections. Patients with extensive internal
contamination were chelated by Prussian blue at doses from 1.5 to 10 g/day. Other measures to increase
137Cs elimination included diuretics combined with water or electrolyte treatment. Mobilization of
137Cs in patients less severely affected was also described. Oral Prussian blue was administered to
46 patients, and 17 patients received oral diuretics. The therapeutic regimen was described as successful.
Based on experimental and clinical observations, the clinically recommended 137Cs antidote
is Prussian blue given orally early after poisoning [13]. While this drug may be lifesaving after
oral exposure, its efficacy after inhalation of 137Cs-contaminated dust is questionable. At present,
no chelating drug is available as nebulizer for mobilization of pulmonary-deposited radioactive
substances. However, the US Food and Drug Administration (FDA) has approved orally given
Prussian blue as a drug for people exposed to radiation contamination (cesium and thallium). The drug
is available as Radiogardase capsules. In addition to oral Prussian blue treatment, acute cases may
require intravenous infusion with appropriate fluids and electrolytes. Adequate clinical chemistry
monitoring, including measurements of blood cell counts, is routinely done. Maintenance of adequate
potassium levels in blood is important. Development of bone marrow depression with leukopenia
may require treatment with a stimulating factor, e.g., Neupogen. In severe cases of pancytopenia, bone
marrow transplantation may be necessary.
4. Radioactive Strontium Contamination
Strontium (Sr), atomic number 38, in Group 2 of the periodic table of elements, standard atomic
weight 226, density 5.5 g/cm3, is a soft silver-white chemically highly reactive metal. Chemically,
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Sr2+ ions have similarities with Ca2+ and Mg2+. Strontium has several known isotopes, of which
89Sr occurs as pollutant around nuclear facilities, and 90Sr is formed as a byproduct during fission
of plutonium and uranium in nuclear reactors and nuclear weapons. Large amounts of 90Sr were
dispersed worldwide during nuclear weapons tests in the 1950s and 1960s. 90Sr decays with β emission
and a half-life of about 29 years. It has been used in the therapy of bone metastases. The intestinal
uptake of Sr2+ is about 30%. Absorbed Sr2+ is mainly deposited in bone with a very long biological
half-time, and thus radioactive strontium increases the risk of bone cancer and leukemia.
Radioactive Strontium Antidotes
Jagtap et al. [18] compared the 85Sr mobilizing effects several calcium salts, including Ca gluconate
(CaG), Ca lactate (CaL), Ca carbonate (CaC) and Ca phosphate (CaP), with that of Ca alginate (CaA),
the latter often advised for Sr2+ mobilization. Rats given 85Sr i.p. or orally were treated with one of
the Ca salts 2 h after 85Sr administration and thereafter once daily. The Ca salts were administered
orally except for CaG, which was administered i.p. in the i.p. Sr group. The diet of experimental
groups was supplemented with the respective Ca salts to 2% elemental Ca. The therapy with Ca salts
significantly reduced the whole-body retention of 85Sr to about half of the retention in controls, as
measured after two weeks. These results indicate that any commonly used Ca salts could replace Ca
alginate for reducing 85Sr body burden.
The clinical use of commercial Ca alginate for internal 85Sr decontamination is limited by its low
solubility. Levitskaia et al. [19] (2010) increased the solubility of alginate by using a low molecular weight
polyethylene glycol/sodium bicarbonate buffer. Oral administration of this alginate solution removed
internal 85Sr in rats significantly. The present clinical recommendation for strontium decorporation is
early initiated long-term treatment with an oral calcium salt. Adjuvant long-term dietary therapy with
alginates may be used. In severe cases of radiation sickness characterized, inter alia, by pancytopenia,
bone marrow transplantation may be necessary.
5. Radioiodine Contamination
Iodine (I) has atomic number 53 and atomic weight 127. It is well known that iodine is important
in nutrition. Iodine’s relatively high atomic number, low toxicity and ease of attachment to organic
compounds have made iodine radioisotopes, such as 131I, a part of many contrast materials in modern
radiology and nuclear medicine. Iodine has only one stable isotope, 127I, with 74 neutrons.
Iodine is found on Earth mainly as the water-soluble iodide. Otherwise, free iodine occurs
mainly as a di-atomic molecule I2. Iodine is the heaviest known essential element to be used by life
in vital biological functions. It is required by higher animals as a component of thyroid hormones.
This element is rare in many soils, leading to many deficiency problems in inland animals and inland
human populations. Like nonradioactive iodine, the radioisotope 131I is taken up and concentrates in
the thyroid.
Radioactive 131I has a decay half-life of about eight days. It decays with both β and γ emission.
Radioactive 131I is used industrially in association with nuclear energy, and plays a major role as a
radioactive isotope present in nuclear fission products. This is because 131I is a major uranium and
plutonium fission product, comprising nearly 3% of the total products. It was a significant contributor
to the health hazards from the Chernobyl and Fukushima accidents [2]. Populations with suboptimal
or deficient iodine intakes will have increased risk of radioiodine accumulation in the thyroid after
such disasters (Figure 2).
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Radioiodine Antidotes
A common treatment method for preventing 131I exposure is by saturating the thyroid with regular,
nonradioactive 127I, as an iodide or iodate salt. When the gland is saturated with nonradioactive iodide,
the thyroid will absorb minimal amounts of the radioactive 131I, thereby avoiding the adverse effects
from radioiodine. The most common method of preventive treatment is to give potassium iodide to
those at risk. The dosage for adults is 130 mg potassium iodide per day, given in one dose or divided
into portions of 65 mg twice a day. This is equivalent to 100 mg of iodine. However, the preventive
ingestion of iodide is not without its dangers. There is reason for caution about taking potassium
iodide or iodine supplements if not necessary, as these doses can disclose or worsen hyperthyroidism
and hypothyroidism, and ultimately cause permanent thyroid disease. The preventive iodide doses
can also cause gastrointestinal disturbances and allergic reactions. Thus, potassium iodide is not
recommended for those who have had an allergic reaction to iodine, and people with severe dermatitis
or vasculitis that are linked to a risk of iodine sensitivity.
Administration of perchlorate, a known goitrogen, has also been shown to reduce radioiodine
uptake. Perchlorate ions competitively inhibit the process by which iodide is actively deposited into
thyroid follicular cells. Although perchlorate can disrupt the thyroid function, this substance remains
very useful as a single dose application to remove radioiodide accumulated in the thyroid.
In the event of a radioiodine release, the ingestion of prophylactic potassium iodide, if available,
should take precedence over perchlorate administration and would be the first line of defense in
protecting the population from a radioiodine release. However, in the event of a radioiodine fallout and
contamination too widespread to be controlled by the stock of iodide, the distribution of perchlorate
tablets would be a cheap second line of defense against carcinogenic radioiodine bioaccumulation.
6. Concluding Remarks
The main purpose of radionuclide mobilization is to minimize the radiation of severely affected
individuals and, in some cases, also remove the chemical insult, in acute cases by measures administered
in a dedicated emergency unit. Since some of the important metal radionuclides have very long
biological half-times after deposition in bone, liver or kidneys, rapid initiation of mobilization treatment
is imperative, to reduce uptake from skin, wounds, lungs or gastrointestinal tract, and to enhance
excretion of circulating radionuclide before tissue deposition. The trained staff in CBRN medicine
should in nuclear accidents work in close cooperation with the expert in nuclear medicine, who should
take part in the important steps in the patient evaluation.
Major strategies in the acute phase include physical cleaning of skin and wounds. In oral
exposures with radiocesium, orally administered Prussian blue can reduce systemic absorption. In the
chronic phase, long-term systemic or oral chelation can promote renal or biliary/fecal excretion of
circulating radionuclides.
Important examples are as follows:
(a) For Cs decorporation, oral Prussian blue is the treatment of choice. In highly contaminated
individuals, such as those in the Goiania accident, this treatment resulted in reduction of whole-body
radiation by a factor of about two. Prussian blue insoluble capsules (Radiogardase, Heyl Co, Germany)
are approved by the FDA for the treatment of internal contamination with radioactive cesium or
thallium. The drug binds cesium in the intestinal tract, thereby also interrupting the enterohepatic
circulation. The resulting excreted complex reduces the effective time of residence of the radioactive
element inside the body. The dose in adults is 3 g given orally every 8 h for at least 30 days. The duration
of therapy is guided by the amount of radioactive cesium that is removed.
(b) For strontium, the present treatment is early initiation and long-term treatment with oral
calcium salts.
(c) Upon exposure to radioiodine, potassium iodide tablets in appropriate doses are the
recommended preventive drug. The US Food and Drug Administration (FDA) as well as the European
Commission for Radiation Protection including the Norwegian Radiation and Nuclear Safety Authority
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have approved the use and preventive distribution of potassium iodide [31,32]. This drug (KI) is used
to saturate the thyroid gland with stable iodine and thus prevent additional subsequent uptake of
radioactive iodine. To be efficacious, KI should be taken before or shortly after the internalization of
radioactive iodine. The dose of KI depends on the age of the patient. The FDA-approved doses of
potassium iodide are as follows: infants less than 1 month old, 16 mg; children 1 month to 3 years,
32 mg; children 3 to 18 years, 65 mg; adults 130, mg [33]. Children younger than 18 years of age
and pregnant women (because of the fetus they are carrying) are more vulnerable to the effects of
radioactive iodine and should be prioritized to receiving this therapy when indicated.
Unfortunately, KI supplements were not distributed to populations living near to the Chernobyl
nuclear power plant after the disaster [25]. On the other hand, the recent accident in Fukushima
highlighted the common misconception that KI is a universal antiradiation pill. Many people took
potassium iodide tablets without proper indication. These actions can cause harm rather than good to
the health of patients [34].
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